1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Antiplatelet regimen timeline
Observation Period Intervention Day 1 after intervention Follow-Up Period Delivery of the First Stent During Intervention 12:00 am 4:00 am 10:00 am ASA 100 mg/day Tirofiban (Aggrastat) i.v., Multiplate test Clopidogrel 300 mg p.o. Tirofiban (Aggrastat) i.v., stopped Multiplate test 1) First 6 months clopidogrel 75 mg/day and ASA 100 mg/day 1) loading dose, 0.4 μg/kg/min (30 min), 1) 15 min after tirofiban start, ASA 100 mg p.o. ASA response? clopidogrel response? 2) lifelong therapy ASA 100 mg/day 2) maintenance dose, 0.1 μg/kg/min 2) end of the intervention, tirofiban response?
Note:—p.o. indicates by mouth; i.v., intravenous.